title: Hypercoagulability resulting from opposite effects of lupus anticoagulants is associated strongly with thrombotic risk.
abstract: Interference of antiphospholipid antibodies (aPL) with coagulation was investigated in 40 aPL-patients (24 with thrombosis) using thrombography. Impairment of the activated protein C anticoagulant pathway was partially offset by the genuine anticoagulant effect. The net result, a procoagulant phenotype, was associated with a 7-fold increased risk of thrombosis in aPL-patients.
authors.forename: Thomas
authors.initials: T
authors.lastname: Lecompte
authors.forename: Denis
authors.initials: D
authors.lastname: Wahl
authors.forename: Christine
authors.initials: C
authors.lastname: Perret-Guillaume
authors.forename: H Coenraad
authors.initials: HC
authors.lastname: Hemker
authors.forename: Patrick
authors.initials: P
authors.lastname: Lacolley
authors.forename: Véronique
authors.initials: V
authors.lastname: Regnault
mesh_terms: D020016:Activated Protein C Resistance / Q000097:blood / Q000276:immunology; D000328:Adult; D000368:Aged; D017152:Antibodies, Antiphospholipid / Q000276:immunology; D016736:Antiphospholipid Syndrome / Q000097:blood* / Q000150:complications / Q000276:immunology; D005260:Female; D006801:Humans; D020128:Inhibitory Concentration 50; D016682:Lupus Coagulation Inhibitor / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D012306:Risk; D019851:Thrombophilia / Q000097:blood* / Q000209:etiology / Q000276:immunology; D013927:Thrombosis / Q000453:epidemiology*
chemical_list: D017152:Antibodies, Antiphospholipid; D016682:Lupus Coagulation Inhibitor